BioLargo
BioLargo is a publicly traded cleantech and life sciences company operating five subsidiaries that commercialize PFAS water treatment (AEC), molten salt battery storage (Cellinity), wound irrigation (ViaCLYR), odor control (CupriDyne), and environmental engineering services for municipal, industrial, and healthcare customers.
- Company typePublic
- Founded2012
- HeadquartersWestminster, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioLargo does
BioLargo, Inc. is a publicly traded cleantech and life sciences company (OTCQX: BLGO) headquartered in Westminster, California, organized into five wholly-owned operating subsidiaries across three U.S. states and one Canadian province: BioLargo Equipment Solutions & Technologies (PFAS water treatment via the Aqueous Electrostatic Concentrator, or AEC), Clyra Medical Technologies (FDA 510(k)-cleared ViaCLYR wound irrigation using Clyrasept copper-iodine antimicrobial technology), BioLargo Energy (Cellinity molten salt battery for grid-scale long-duration energy storage), BioLargo Engineering, Science & Technologies (BLEST, environmental engineering and consulting), and ONM Environmental (CupriDyne odor and VOC control).
The company's technology portfolio is anchored by 20+ patents held by CSO Kenneth Code, including the AEC electrostatic PFAS concentration system (which achieves >90% energy reduction and avoids secondary waste streams compared to activated carbon or ion exchange), the Cellinity liquid sodium battery (positioned as a rare-earth-free alternative to lithium-ion for AI infrastructure and grid-scale storage), the Clyrasept copper-iodine complex powering ViaCLYR, and the CupriDyne odor control platform (historically licensed to Pooph Inc. before the agreement was revoked in 2025 for non-payment of $3.85 million).
BioLargo monetizes through a hybrid model spanning direct equipment sales (AEC municipal deployments), channel-exclusive distribution (Advanced Solution LLC for ViaCLYR in the U.S., Al-Hikma FZCO for MENA), technology integration partnerships (Aquatech MOU for global AEC deployment), engineering service contracts (BLEST), licensing (CupriDyne, historically), and emerging third-party-validated licensing opportunities (Cellinity). The company reported 2025 revenue of $7.8 million (down 56% year-over-year following the Pooph termination), a $15.2 million net loss, and a $3.9 million cash position, while securing its first commercial AEC installation (Lake Stockholm, NJ), its first ViaCLYR stocking order, and two material international distribution and technology partnerships in early 2026.
BioLargo firmographics
Firmographics- Name
- BioLargo
- Legal name
- BioLargo, Inc.
- Website
- https://biolargo.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioLargo is a publicly traded cleantech and life sciences company operating five subsidiaries that commercialize PFAS water treatment (AEC), molten salt battery storage (Cellinity), wound irrigation (ViaCLYR), odor control (CupriDyne), and environmental engineering services for municipal, industrial, and healthcare customers.
- Ownership category
- akta.pro rank
BioLargo industry classification
Industry- Product category
- Environmental Technologies
- NAICS
- Chemical Manufacturing (325), Soap and Cleaning Compound Manufacturing (32561), Automatic Environmental Control Manufacturing for Residential, Commercial, and Appliance Use (334512)
- SIC
- Services-Commercial Physical & Biological Research (8731), Industrial & Commercial Fans & Blowers & Air Purifing Equip (3564)
- akta.pro primary industry
- Water Treatment & Process Specialty Chemicals (IMAEABAN)
- akta.pro secondary industry
- Biocides & Disinfection Chemicals (Non-Agricultural) (IMAEAJAL)
Keywords
Where BioLargo is headquartered
LocationHeadquarters
- HQ city
- Westminster
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
BioLargo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Engineering Services Revenue: BioLargo Engineering, Science & Technologies (BLEST) provides full-service environmental engineering and consulting including compliance, permitting, process design, and more. Revenue from third-party engineering services grew 98% year-over-year, reaching $2 million for 2025. The subsidiary was awarded a $1.2M contract to design a pilot-scale minerals processing facility in April 2026.
- Licensing and Royalty Revenue: BioLargo monetizes its proprietary technologies through licensing agreements. The CupriDyne technology was licensed to Pooph Inc., which built a nationally recognized consumer brand reaching over $50M in annual sales before the license was revoked in 2025 for non-payment ($3.85M owed). The company continues to pursue licensing and channel partnerships for its technologies.
- Product Sales (Medical Devices): Clyra Medical Technologies commercializes wound care products (ViaCLYR) through distribution agreements. The company secured its first commercial stocking order from Advanced Solution in February 2026, marking the transition to revenue-generating operations. International distribution is handled through Al-Hikma FZCO for Middle East and North Africa markets.
- Product and Equipment Sales (Water Treatment): BioLargo Equipment sells and deploys PFAS treatment systems (AEC) directly to municipal and industrial clients. The first commercial deployment was the Lake Stockholm municipal water facility installation in New Jersey. Revenue model includes direct sales combined with channel partnerships (Aquatech MOU) for broader market reach.
- Government and Research Grants: BioLargo has secured over 90 awarded research grants across its history. Dr. Richard Smith at BioLargo Water has secured over 60 research grants. Grants support R&D for water treatment, PFAS remediation, and other environmental technologies. The company leverages academic, municipal, and commercial collaborations.
- Battery Technology (Emerging): BioLargo Energy's Cellinity battery technology is in development and evaluation phase. U.S. BESS Corporation conducted an independent evaluation confirming breakthrough performance for grid-scale energy storage. The company positions this as targeting the large AI infrastructure investment cycle. Not yet generating material revenue.
Go-to-market motion4 records
Distribution channels6 records
Marketing channels9 records
BioLargo product offering
Product offeringCore offering
BioLargo develops, manufactures, and commercializes patented cleantech and life sciences innovations through five subsidiaries. Core offerings include the Aqueous Electrostatic Concentrator (AEC) for PFAS water treatment, the AOS advanced oxidation system for water and wastewater treatment, the Cellinity molten salt battery for grid-scale energy storage, CupriDyne odor and VOC control systems, the FDA-cleared ViaCLYR wound irrigation solution powered by Clyrasept copper-iodine complex technology, and full-service environmental engineering consulting via BLEST.
Product overview
BioLargo is a multi-subsidiary cleantech and life sciences company organized into Environmental Group subsidiaries (BioLargo Equipment, BioLargo Engineering, BioLargo Energy, ONM Environmental) and a medical subsidiary (Clyra Medical). The company commercializes innovations across four core technology areas: (1) PFAS water treatment via the Aqueous Electrostatic Concentrator (AEC) - a patented system that removes and destroys 'forever chemicals' without secondary waste; (2) Long-duration energy storage via the Cellinity liquid sodium battery technology that eliminates rare earth elements; (3) Odor and VOC control via CupriDyne Clean technology including former private-label Pooph product; and (4) Wound care via Clyra Medical's ViaCLYR irrigation solution powered by Clyrasept copper-iodine complex technology (FDA-cleared). The company monetizes through direct sales, engineering services, licensing agreements, and strategic partnerships.
Differentiator
Problem solved
Functional benefit
Brands
- ONM Environmental: Odor control and VOC control solutions for industrial applications, including the CupriDyne Clean technology platform
- CupriDyne Clean
- Pooph
- BioLargo Equipment
- AEC (Aqueous Electrostatic Concentrator)
- Clyra Medical
- ViaCLYR
- BioLargo Energy
- Cellinity
- BioLargo Engineering
Products and services
- Aqueous Electrostatic Concentrator (AEC) Patented PFAS water treatment technology that uses electromotive force to collect and immobilize 'forever chemicals' directly onto membrane surfaces without generating secondary concentrated liquid waste. Designed for municipal drinking water, industrial wastewater, and environmental cleanup applications.
Quantifiable outcome
- >90% energy reduction in AEC PFAS treatment compared to prior generations
- +4 more outcomes
Companies that use BioLargo
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles5 records
BioLargo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
BioLargo partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and supporting.
- Major Unnamed PFAS Remediation Industry PartnercoreBioLargo CEO Dennis Calvert announced during a shareholder/analyst call that the company has established a strategic partnership with a major industry player to jointly serve customers globally with PFAS remediation solutions. The partnership combines both companies' technologies and the CEO stated the PFAS market is shifting dramatically with press coverage expected to follow. The specific partner name and deal value were not disclosed. This partnership complements the Aquatech MOU and other PFAS commercialization efforts.
- Al-Hikma FZCOcoreClyra Medical Technologies signed an exclusive distribution agreement with Al-Hikma FZCO (Dubai, UAE) to commercialize ViaCLYR wound irrigation solution across Gulf Cooperation Council, Levant, North Africa, and adjacent markets. Al-Hikma was founded in 2005 by Dr. Ali Farooq Abdul-Qader, exports to ~25 countries, maintains 50+ local distributor partnerships, employs ~500 people, and serves a population of 500+ million. Territory exclusivity is tied to performance milestones, and regulatory work is already underway in key markets for commercial sales approval.
- AquatechcoreBioLargo Equipment signed a non-exclusive MOU with Aquatech, a globally recognized water treatment company awarded Water Technology Company of the Year at the 2025 Global Water Summit. The agreement establishes a framework for integrating BioLargo's proprietary Aqueous Electrostatic Concentrator (AEC) technology into Aquatech's end-to-end PFAS treatment solutions. The AEC serves as a concentration and collection step within Aquatech's full flowsheet solutions for PFAS destruction, enabling deployment for industrial, municipal, and government clients worldwide.
- Advanced Solution LLCcoreClyra Medical Technologies signed an exclusive stocking distribution agreement with Advanced Solution LLC for ViaCLYR wound irrigation solution. The partnership leverages Advanced Solution's national network for U.S. market coverage. First commercial stocking order received in February 2026, marking Clyra Medical's transition to revenue-generating operations. ViaCLYR is Clyra's FDA-cleared wound irrigation solution powered by Clyrasept copper-iodine complex technology.
- U.S. BESS CorporationsupportingU.S. BESS Corporation conducted an independent evaluation confirming the breakthrough performance of BioLargo's Cellinity battery technology for grid-scale energy storage. The evaluation highlighted the technology's resistance to thermal runaway and use of recyclable materials without rare earth elements. This third-party validation supports BioLargo's go-to-market efforts for the Cellinity molten salt battery targeting AI infrastructure and grid-scale storage markets.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
BioLargo competitors and assessment
Company assessmentDirect peers
- Aquatech: Global water treatment company specializing in PFAS and industrial water solutions. While also a current BioLargo partner (May 2026 MOU), Aquatech offers integrated PFAS destruction flowsheets that include concentration/collection steps, making it both a collaborator and a competitive benchmark for AEC technology.
- Form Energy: Long-duration energy storage company developing iron-air battery technology for grid-scale applications (100+ hour discharge). The most direct competitor to BioLargo's Cellinity molten salt battery in targeting AI infrastructure, renewable integration, and utility-scale LDES customers.
- ESS Inc. Public long-duration energy storage company using iron flow battery technology for commercial and utility-scale applications. Direct comparable to Cellinity in the long-duration storage category, particularly for renewable energy and microgrid customers.
Emerging players
- Cyclopure: Emerging PFAS removal technology company using novel adsorbent materials for water treatment. Directly comparable to BioLargo's AEC as a next-generation PFAS remediation approach targeting municipal and industrial water customers seeking alternatives to activated carbon.
- Regenesis: Environmental remediation technology company offering in-situ and ex-situ treatment solutions including for PFAS-impacted sites. Comparable to BioLargo's BLEST engineering and PFAS remediation capabilities for industrial and government environmental projects.
Broad incumbents
- Xylem (Evoqua): Major water technology company with broad PFAS treatment, water reuse, and municipal water solutions. Acquired Evoqua Water Technologies in 2023 to expand PFAS capability; represents the established incumbent BioLargo must displace in municipal water RFPs.
- Veolia Water Technologies: Global water and wastewater treatment major with extensive PFAS, industrial water, and reuse offerings. Represents the dominant incumbent in the municipal and industrial water treatment markets where BioLargo Equipment is selling AEC systems.
- Smith+Nephew: Global medical device company with a major Advanced Wound Management division. Represents the established incumbent in wound care that ViaCLYR must compete against for hospital, clinic, and chronic wound market share.
- Convatec: Specialty medical device company focused on advanced wound care, ostomy, and continence care. A relevant incumbent peer for Clyra Medical's ViaCLYR wound irrigation solution, particularly in chronic wound and surgical site infection applications.
- Tetra Tech: Leading global consulting and engineering firm specializing in water, environment, and sustainable infrastructure. The most direct comparable to BioLargo's BLEST environmental engineering subsidiary for federal, municipal, and industrial environmental remediation projects.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioLargo social profiles
Digital presenceBioLargo financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioLargo leadership team
Management profileNumber of profiles
Profiles16 records
BioLargo subsidiaries and ownership
Company hierarchySubsidiaries6 records
BioLargo funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioLargo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioLargo
What does BioLargo do?
BioLargo develops, manufactures, and commercializes patented cleantech and life sciences innovations through five subsidiaries. Core offerings include the Aqueous Electrostatic Concentrator (AEC) for PFAS water treatment, the AOS advanced oxidation system for water and wastewater treatment, the Cellinity molten salt battery for grid-scale energy storage, CupriDyne odor and VOC control systems, the FDA-cleared ViaCLYR wound irrigation solution powered by Clyrasept copper-iodine complex technology, and full-service environmental engineering consulting via BLEST.
Is BioLargo a public or private company?
BioLargo is a public company. It is classified as public and is currently operating.
When was BioLargo founded?
BioLargo was founded in 2012. It employs 11 to 50 people.
Where is BioLargo based?
BioLargo is headquartered in Westminster, United States, in the North America region.
How does BioLargo make money?
Six revenue lines are on record. Engineering Services Revenue is the primary driver. The others are licensing and Royalty Revenue, product Sales (Medical Devices), product and Equipment Sales (Water Treatment), government and Research Grants and battery Technology (Emerging).
Who are BioLargo's main competitors?
Direct peers on record are Aquatech, Form Energy and ESS Inc.. Emerging players are Cyclopure and Regenesis. Broad incumbents are Xylem (Evoqua), Veolia Water Technologies, Smith+Nephew, Convatec and Tetra Tech.
Does BioLargo have an API?
No public API is recorded for BioLargo.
What industry is BioLargo in?
BioLargo's product category is Environmental Technologies. Its primary akta.pro industry code is IMAEABAN, Water Treatment & Process Specialty Chemicals, with a secondary code of IMAEAJAL, Biocides & Disinfection Chemicals (Non-Agricultural). Its NAICS code is 325 and its SIC code is 8731.